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Sputum epithelial cell-derived neutrophil-activating peptide-78 
(ENA-78/CXCL5) in asthmatic children: relation to eosinophil activation 
 
INTRODUCTION 
Airway inflammation is a characteristic feature of 
bronchial asthma. It contributes significantly to 
many features of this disease, including airflow 
obstruction, bronchial hyperresponsiveness, and the 
initiation of the injury-repair process (remodeling) 
found in some patients1. Assessing airway 
inflammation is important for investigating the 
mechanism and following the progression and 
resolution of the disease. This is difficult to be 
detected clinically, and may result in delays in 
initiating appropriate therapy. Thus, assessing 
biological markers of airway inflammation for 
proper diagnosis, monitoring and treatment of 
bronchial asthma is essential2. 
Sputum induction is a non-invasive test that 
monitors airway inflammation. It samples the lower 
airways more directly, it is considered a good 
alternative to fibro-optic bronchoscopy and it 
correlates well with data from bronchial biopsies 
and bronchoalveolar lavage3. Sputum markers tend 
to be more sensitive than blood tests when 
assessing airway inflammation4. 
Chemokines are a large group of chemotactic 
cytokines. They have been divided into four groups, 
designated CXC, CC, C and CX3C, depending on 
the spacing of conserved cytokines (where X is an 
amino acid). The CXC chemokines mainly target 
neutrophils and lymphocytes whereas the CC 
chemokines target a variety of cell types, including 
macrophages, eosinophils, basophils and dendritic 
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cells5. Recruitment of inflammatory cells is a hall 
phenomenon of all inflammatory diseases, 
including allergic asthma. Not only are chemokines 
involved in recruitment of these cells, but they also 
play a role in their activation and differentiation6.  
Eosinophils are the chief effector inflammatory 
cells contributing to the pathogenesis of bronchial 
asthma. Activated eosinophils in asthmatic patients 
release their granular proteins. One such protein is 
eosinophil cationic protein (ECP) that has an 
essential role in the pathogenesis of airway 
hyperresponsiveness due to its cytotoxic effect on 
airway epithelial cells7.  
Epithelial cell-derived neutrophil-activating 
peptide-78 (ENA-78/CXCL5), is a CXC chemokine 
that attracts neutrophils8. In the healthy lung, 
epithelial cells are the primary source of 
chemokines, while in the inflamed lung infiltrating 
cells within the submucosa are the major cellular 
source of chemokines9. Immunocytochemistry 
detected ENA-78 in eosinophils and the peptide 
was localized in the specific granules. This may 
suggest that, through expression of ENA-78, 
eosinophils can recruit and activate CXC receptor 2 
(CXCR2)-bearing cells such as neutrophils at sites 
of inflammation. Eosinophils may also promote 
connective tissue remodeling through release of this 
peptide. Thus, eosinophils are not just mere targets 
for chemokines, but are also able to elaborate these 
factors in a manner that suggests an important 
immunoregulatory role10. 
Chemokines and their receptors are important 
potential therapeutic targets in allergy and asthma 
because of their central role in cell recruitment and 
activation during inflammation6. Targeting the 
chemokine system is generally done by affecting 
chemokine receptor binding which can be done in 
three ways: by using blocking antibodies, by 
modification of chemokines and therefore 
antagonizing chemokine receptors and by using 
small molecule chemokine receptor antagonists11.  
This study was conducted to measure sputum 
ENA-78 in relation to acute asthma exacerbation of 
varying severity, ECP, as a marker of eosinophil 




Study population   
This case-control, follow-up study was conducted 
on 21 asthmatic children recruited from the 
Pediatric Allergy and Immunology Clinic, 
Children’s Hospital, Ain Shams University, over a 
period of 9 months. They were 14 (66.7%) males 
and 7 (33.3%) females, their ages ranged between 6 
and 16 years with a mean age of 9.7 ± 3.7 years. 
Patients were subdivided according to the severity 
of acute asthma exacerbation into three equal 
subgroups; mild, moderate and severe.  
The diagnosis of asthma was based on the 
clinical symptoms and signs of episodic wheezing, 
chest tightness, dyspnea and nocturnal symptoms 
that improved at least partially after bronchodilator 
therapy. Patients were studied within 24 hours of 
the start of an acute asthma exacerbation. The 
severity of acute asthma exacerbations was 
classified by symptoms (breathlessness, talking and 
alertness), signs (respiratory rate, use of accessory 
muscles, wheezes, pulse/min and pulses paradoxus) 
and functional assessment (peak expiratory flow 
rate "PEFR") following the National Heart, Lung 
and Blood institute, expert panel report 2, 200212. 
Patients were excluded form the study if they had 
respiratory infection ruled out by the absence of 
clinical manifestations and chest radiograph 
findings.     
Patients with acute asthma exacerbation were 
followed up for 2-3 weeks until stabilization of 
their condition and quiescence of asthma symptoms 
by treatment (i.e. remission or steady state). Then, 
follow-up blood and sputum samples were 
collected. 
Twenty-one healthy children without a history 
of asthma or other atopic conditions and without 
family history of atopy were studied as controls. 
They were 14 (66.7%) males and 7 (33.3%) 
females, their ages ranged between 6 and 16 years 
with a mean age of 9.8 ± 3.8 years.  
An informed consent was obtained form the 
parents or caregivers of each child before 
enrollment in the study. 
 
Study measurements  
Measurement of peak expiratory flow rate: 
Mini-Wright Peak Flow Meter (Clement Clarke 
International Ltd, Harlow, England) was used. 
Since the parents did not know their children's 
personal best, the estimation of the expected PEFR 
was obtained from a standardized chart that 
approximates PEFR by the child's height13. The 
PEFR of each patient was compared with the 
normal population and % predicted was calculated.  
Assessment of complete blood count: One mL of 
venous blood was collected into sterile EDTA tubes 
and assayed by Coulter counter on the same day 
(Coulter Microdiff 18, Coulter Corp, Miami FL, 
USA). The differential leucocytic counts were 
counted manually from the blood film and 
expressed in absolute count values. The patient was 
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considered to have elevated blood eosinophil count 
if it was above 400 cells /mm3. 
Immunoglobulin E assay: serum total IgE was 
assayed by ELISA (Eurogenetics, IgE Quantitative, 
Tessen Derlo, Belgium). Results were expressed in 
IU/mL. Owing to the variability in serum total IgE 
levels with age in childhood, we calculated the 
percentage values from the reference ranges14 by 
dividing the subject’s level by the highest normal 
for age x 100. 
Assessment of serum ECP: In the assay, the solid 
phase "a polysterene bead enclosed within an 
immulite test unit" is coated with a monoclonal 
antibody reactive to ECP, while the patient sample 
and alkaline phosphatase conjugated poloyclonal 
antibody are incubated for 30 min. at 37oC. ECP in 
the sample is bound to form an antibody sandwich 
complex. Unbound conjugated antibody is removed 
by a centrifugal wash after which the substrate 
(adamantly dioxetane phosphate) is added and the 
test unit is incubated for further 10 minutes. 
Dephosphorylation of this substrate would result 
into production of an unstable union intermediate. 
Continuous production of this intermediate, resulted 
in sustained emission of light which is directly 
proportional to ECP in the sample15. As the data 
distribution was non-parametric, a patient was 
considered to have elevated serum ECP if it was 
above 18 ng/ml which was above the 95th percentile 
of the control values. 
Sputum induction: Subjects under study were 
selected above 5 years of age so that adequate 
sputum samples can be obtained spontaneously 
when required. Sputum was induced only when it 
could not be produced spontaneously. The sputum 
induction was performed as a modification of the 
method described by Fahy et al.16. All subjects were 
premedicated with two puffs inhaled sulbutamol 
(200 μg) 30 minutes before sputum induction. To 
minimize contamination with saliva and postnasal 
drip, subjects were asked to rinse their mouths and 
blow their noses before induction and, wherever 
possible, before expectoration. Subjects inhaled 3% 
hypertonic saline solution aerosols generated by 
Farmasol compressor nebulizer (CA-MI s.n.c., 
Pilastro PR, Italy). Hypertonic saline was inhaled 
for 10-15 minutes according to the severity of 
asthma until an adequate volume of sputum was 
expectorated. Patients were asked to cough deeply 
and frequently during hypertonic saline inhalation. 
They were asked to cough the sputum into a sterile 
plastic container. The sample volumes and duration 
of sputum induction were recorded. Sputum 
induction was stopped if the PEFR% predicted fell 
by > 15%.  
Measurement of sputum eosinophils: sputum was 
selected form saliva and processed within 2 h. The 
method of sputum examination described by Popov 
et al.17 was modified18. Sputum obtained was  
treated by adding equal volumes of 0.1% of 
dithiothreitol (ICN Biomedicals, Inc., Irvine, CA, 
USA), followed by equal volumes of Dulbecco's 
phosphate buffered saline (D-PBS). The sample 
was then    mixed gently and placed in shaking 
water bath at 37oC for 15 min to ensure complete 
homogenization. The sample was removed form the 
water bath periodically for further brief gentle 
mixing. Then, centrifugation was  carried  out at 
1500 x g for 15 min. The cell pellet was spread on a 
slide that was stained with Leishman and a 
differential cell count of 400 non squamous cells 
was performed. Eosinophils in sputum are 
expressed as percentage of leucocytes. Evaluation 
was carried out by a single person, blind to the 
clinical conditions of the patients. As data 
distribution was non-parametric, patients were 
considered to have elevated sputum eosinophils % 
if it was above 2% (the 95th percentile of the control 
values).  
Assessment of sputum ENA-78: Sputum samples 
were filtered through a two layer sterile gauze into 
sterile plastic vials (falcon, Oxnard, CA), 
centrifuged  at 4oC and 500g for 10 minutes. The 
supernatant was removed and stored at -70oC until 
assay of ENA-78. This assay employs the 
quantitative sandwich enzyme immunoassay 
technique (R and D systems Inc., 614 Mclinley 
Place NE Minenopolis MN 55413, USA). A 
monoclonal antibody specific for ENA-78 has been 
pre-coated onto a microplate. Standards and 
samples are pipetted into the wells and any ENA-78 
present is bound by the immobilized antibody. 
After washing away any unbound substances, an 
enzyme-linked polyclonal antibody specific for 
ENA-78 is added to the wells. Following a wash to 
remove any unbound antibody-enzyme reagent, a 
substrate solution is added to the wells and color 
develops in proportion to the amount of ENA-78 
bound in the initial step. The color development is 
stopped and the intensity of the color is measured 
by ELISA recorder19. The patient was considered to 
have an elevated sputum ENA-78 level if it was 
above the chosen highest cut-off value "82.8 pg/ml" 
which was the 95th percentile of control values 
because data distribution was non-parametric. 
 
Statistical analysis:  
The results were analyzed by commercially 
available software package (Stat View, Abacus 
Concepts, Inc, Berkley, CA, USA). The data were 
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presented as mean and standard deviation (SD) in 
addition to median and interquartile range (IQR) 
which is the difference between the 75th and 25th 
percentiles. Mann Whitney test was used for 
comparison between 2 groups as data distribution 
was non-parametric. Wilcoxon signed rank test was 
used for comparison between the same groups 
during and after exacerbation. Spearman’s 
correlation coefficient “r” was used to determine 
the relationship between different quantitative 
variables. For all tests, a probability (p) of less than 




Sputum ENA-78 in relation to acute asthma 
exacerbation of varying severity: 
Children with acute asthma exacerbation had 
significantly higher levels of sputum ENA-78 than 
healthy controls. When patients with acute asthma 
exacerbation were followed-up till remission, 
sputum ENA-78 levels decreased significantly but 
its levels remained significantly higher than healthy 
controls (table 1). In addition, sputum ENA-78 
levels were significantly higher in severe than mild 
and moderate and in moderate than mild 
exacerbations (table 2). 
 
Sputum ENA-78 in relation to steroid therapy  
Sputum ENA-78 levels were significantly higher in 
patients who were receiving inhalation and/or 
systemic steroid therapy (n = 8; 2 had moderate and 
6 had severe exacerbations) than in those who were 
not (n = 13; 7  had mild, 5 had moderate and one 
had severe exacerbations). Figure 1. 
 
Serum eosinophil cationic protein and eosinophil 
counts in blood and sputum in relation to acute 
asthma exacerbation of varying severity: 
Patients with acute asthma exacerbation had 
significantly higher levels of serum ECP, blood 
eosinophil counts and sputum eosinophils % than 
healthy controls. When these patients were 
reexamined during remission, the levels of these 
inflammatory markers decreased significantly in 
spite of still being significantly higher than 
controls. Serum ECP levels were significantly 
higher in severe than mild and moderate and in 
moderate than mild exacerbation. In contrast, blood 
eosinophil counts did not differ significantly 
between patients with mild, moderate and severe 
exacerbation. On the other hand, sputum 
eosinophils % were significantly higher in severe 
than mild and moderate exacerbation, but their 
levels in patients with mild and moderate 
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Figure 1. Sputum ENA-78 levels in relation to steroid therapy. 
The boxes enclose the interquartile ranges (IQR) which are between the 25th and 
75th percentiles. The horizontal line inside the box represents the median and the 
whiskers represent the non outlier or extreme maximum and minimum values. 
   
 
Percentage of patients with elevated levels of the 
studied inflammatory markers for acute asthma 
exacerbation: 
In asthmatic children, whether compiled in one 
group or subdivided into mild, moderate and severe 
according to exacerbation severity, sputum ENA-78 
recorded the highest percentage of elevation among 
patients followed by serum ECP and sputum 
eosinophils %. The least percentage of elevation 
among patients was of blood eosinophil counts 
(table 4).    
Correlation between sputum ENA-78 and the 
other studied inflammatory markers of 
bronchial asthma during exacerbation:   
Sputum ENA-78 had significant negative correlation 
with PEFR. On the other hand, sputum ENA-78 had 
significant positive correlation with serum ECP, blood 
eosinophil count, sputum eosinophils % (figure 2) and 
serum IgE (r = 0.5, p< 0.05).  
In contrast, sputum ENA-78 did not correlate 
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z1 (p) 4.5 (< 0.0001)** 5.3 (<0.0001)** 4.5 (<0.0001)** 
z2 (p) 2.5 (<0.05)* 3.2 (<0.01)** 3.1 (<0.01)** 
z3 (p) 3.98 (<0.0001)** 3.22 (<0.01)** 3.87 (<0.0001)** 
z4 (p) 2.2 (<0.05)* 1.28 (>0.05) 0.27 (>0.05) 
z5 (p) 2.3 (<0.05) 1.6 (>0.05) 2.4 (<0.05)* 
z6 (p) 2.4 (<0.05)* 1.6 (>0.05) 2.3 (<0.05)* 
ECP: eosinophil cationic protein, p>0.05: non significant, p<0.05*: significant, p<0.01**, 0.0001**: highly 
significant, z1: comparison between asthmatic patients during exacerbation and controls, z2: comparison 
between asthmatic patients during remission and controls, z3: comparison between asthmatic patients during 
and after exacerbation, z4: comparison between patients with mild and moderate exacerbation z5: comparison 
between patients with mild and severe exacerbation, z6:  comparison between patients with moderate and severe 




Table 4.  Percentage of patients with elevated levels of the studied inflammatory 




















(n = 7) 
Sputum ENA-78 95.2% 85.7% 100% 100% 
Serum ECP  80.9% 71.4% 85.7% 85.7% 
Sputum 
eosinophils% 71.4% 57.1% 71.4% 85.7% 
Blood eosinophil 
count 57.1% 43% 57.1% 71.4% 






































































































































Figure 2. Negative correlation between sputum ENA-78 and PEFR (Fig. 2A) and positive 
correlation between sputum ENA-78 and serum ECP (Fig. 2B), sputum eosinophils % (Fig. 2C) 




Epithelial cell-derived neutrophil-activating 
peptide-78 is an inflammatory C-X-C chemokine 
that is encoded  by  the CXCL5 gene20. Its levels 
were elevated in myriad inflammatory 
conditions21,22 including pulmonary disease23. In our 
series, sputum ENA-78 was significantly higher in 
asthmatic patients during exacerbation than healthy 
controls. A previous study investigated the 
relationship between ENA-78 and rhinovirus (RV) 
infection-induced bronchospasm as asthma 
exacerbations are frequently associated with RV 
infection. Nasal ENA-78 levels were significantly 
elevated in asthmatic patients with than those 
without RV infection as RV16 induced 3-fold 
increases in ENA-78 gene transcription. Thus, 
ENA-78 may be produced by bronchial epithelial 
cells in response to RV16 infection resulting in 
initiation of neutrophil airway inflammation and 
development of virus associated airway pathologies 
as bronchospasm24. 
ENA-78 is an α chemokine which is produced 
concomitantly with IL-8 and melanoma growth 
stimulating activity8. The main stimuli for secretion 
of chemokines including ENA-78, are the early 
signals elicited during innate immune response. For 
example, bacterial products, viral infection and pro-
inflammatory cytokines25. Notably, chemokines are 
induced rapidly, within one hour, by these triggers 
and provide an important link between early innate 
immune responses and adaptive immunity9. ENA-
78 can act in concert with IL-8 to stimulate 
neutrophil directed chemotaxis, neutrophil  
activation via increasing the intracellular level of 
free calcium and elastase release and  it can also 
induce neutrophil proadhesive activity21,22. 
Neutrophils contribute to the development of 
allergic asthma as they play a role in tissue 
remodeling. This ability stems in part from the 
angiogenic property of a subgroup of neutorphil 
activating CXC chemokines including ENA-7826. 
In our series, sputum ENA-78 levels measured 
during exacerbation had significant positive 
correlation with serum total IgE levels. Such 
finding added to the increasing evidence that this 
chemokine may be implicated in asthma 
r = 0.89, p < 0.0001 
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pathophysiology as IgE is closely related to the 
pathogenesis of asthma. However, a good number 
of atopic asthmatics have normal total serum IgE 
levels13. 
Eosinophilia measured both in the peripheral 
circulation and in the airways is a characteristic 
feature of asthma26. This was also the case in our 
study  as asthmatic patients had significantly higher 
blood  and sputum eosinophil counts than controls. 
Similar findings were reported by other 
investigators27,28. In addition, activation and 
degranulation of eosinophils, the chief effector 
inflammatory cells in bronchial asthma, release a 
wide variety of tissue damaging products capable of 
worsening this condition26. One such product is 
ECP which has an essential role in the pathogenesis 
of airway hyperresponsivneess due to its cytotoxic 
effect on airway epithelial cells7. In the present 
work, children with acute asthma exacerbation had 
significantly higher serum ECP than healthy 
controls. Other investigators also reported elevated 
serum ECP during acute asthma exacerbation29.  
In our study, sputum ENA-78 had significant 
positive correlation with ECP and eosinophil counts 
in blood and sputum. Some investigators reported 
that eosinophils express enhanced levels of ENA-78 
in their specific granules detected by immuno-
electron microscopy suggesting that eosinophils are 
capable of recruiting  and activating CXCR2 
bearing cells, such as neutrophils through the 
release of this chemokine10.  
Treatment applications in asthma are based 
upon disease severity. Since asthma is a chronic 
disease whose severity may change over time, it is 
important to adjust treatment to appropriately match 
treatment requirements with disease severity. 
Failure to do this leads to under-treatment with the 
associated  risk of impaired quality of life and 
severe exacerbations. Alternatively over-treatment 
may occur, with the risk of excessive adverse 
effects. At present, symptoms and lung functions 
are used to monitor asthma severity and adjust 
treatment. These measures are imperfectly 
correlated with the underlying pathophysiological 
process in asthma, namely airway 
hyperresponsivenss and airway inflammation. 
Using objective measures of airway hyper-
responsiveness and airway inflammation may lead 
to better management of asthma30. 
In the present work, sputum ENA-78 correlated 
positively with the disease severity as evidenced by 
the graded increase in its levels that went hand in 
hand with the degree of severity of asthma 
exacerbation. Another finding which supported this 
argument was the significant negative correlation 
between sputum ENA-78 and PEFR. Thus, the 
relationship between ENA-78 and bronchial asthma 
may be a causal one in which this chemokine may 
not only play a role in the evolution of acute asthma 
exacerbation, but its levels may also determine its 
clinical severity. We could not trace data in the 
literature that address the relationship between 
ENA-78 and the severity of acute asthma 
exacerbation. Thus, broad scale studies are 
warranted to set cut-off values of ENA-78 for each 
grade of asthma severity. Indeed, this will allow for 
a better management of asthma exacerbations.     
In contrast to sputum ENA-78, blood 
eosinophil count did not correlate significantly with 
the severity of acute asthma exacerbation. Also, 
sputum eosinophils % did not accurately reflect the 
severity of asthma exacerbation as there were no 
significant differences between mild and moderate 
exacerbations. Some investigators reported that 
eosinophil cell numbers do not necessarily equate 
with function as hypodense eosinophils (eosinophils 
with lower density, and greater number of 
immunoglobulin receptors) better reflect the 
severity of asthma than the mere count of peripheral 
blood eosinophils. These hypodense cells are 
metabolically more active and proinflammatory 
than its normal dense counter parts and they are 
important in the cascade of events which often 
determines asthma severity31. Thus, the significant 
positive correlation between sputum ENA-78 and 
asthma severity, serum ECP, eosinophil counts in 
blood and sputum and serum IgE may denote that 
this chemokine may reflect the inflammatory 
process in bronchial asthma even in patients with 
mild exacerbations in the meantime when 
eosinophil counts in blood and sputum were not 
elevated in a large proportion of these patients. 
Corticosteroid-treated asthmatic patients had 
significantly higher levels of sputum ENA-78 than 
non-steroid treated patients. This was surprising 
because corticosteroids were supposed to control 
the inflammation of the airways with subsequent 
decrease of the levels of the inflammatory indices. 
This could be explained by the fact that 
corticosteroids were used mostly by inhalation in 
our patients categorized to have severe asthma 
exacerbations. In spite of steroid therapy, acute 
severe exacerbations may result from failure of 
many children to introduce the medication into their 
lung especially in absence of spacer or air chamber 
delivery systems.  
In the present work, although sputum ENA-78, 
serum ECP and eosinophil counts in blood and 
sputum were significantly lowered during asthma 
quiescence, yet their levels remained significantly 
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higher than those of controls. Other investigators 
reported lower eosinophil number in blood and 
eosinophil proteins levels in serum (ECP and 
eosinophil peroxidase) in healthy children than in 
the symptom – free asthmatic children32. These 
findings may denote that in spite of apparent 
clinical quiescence of bronchial asthma, there is 
underlying inflammation with release of 
chemokines such as ENA-78 from eosinophils. This 
undermines the importance of clinical examination 
alone as a guide to the subsidence of asthma 
exacerbation. This also highlights the importance of 
searching for inflammatory markers of bronchial 
asthma such as ENA-78 for the objective 
measurement of asthma quiescence.  
In conclusion, sputum ENA-78 is increased 
during acute asthma exacerbations, and its levels 
closely follows its severity, and positively 
correlates with markers of eosinophil activation. 
Thus, ENA-78 possibly plays a role in the evolution 
of acute asthma exacerbation and hence, it may be a 
target for new therapy of asthma exacerbations. 
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